No trades
See on Supercharts
Overview
Financials News Ideas Minds Technicals Forecast
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
Market capitalization
775.16 MUSD
—
—
−0.44USD
−78.02 MUSD
175.51 MUSD
128.69 M
Beta (1Y)
1.92
About Aurinia Pharmaceuticals Inc
Sector
Industry
CEO
Peter S. Greenleaf
Website
Headquarters
Edmonton
Employees (FY)
300
Founded
1993
FIGI
BBG000BCRJM5
Aurinia Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Victoria, Canada.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
0.00
AUPH Aurinia Pharmaceuticals Options Ahead of EarningsAnalyzing the options chain and the chart patterns of AUPH Aurinia Pharmaceuticals prior to the earnings report this week,I would consider purchasing the 7usd strike price Calls withan expiration date of 2024-3-15,for a premium of approximately $1.50.If these options prove to be profitable prior
Long
Cup and handle on daily This is a bullish sign. I think the stock will break 52 week high soon.
Long
AUPH inside days after good run up. $AUPH AUPH inside days after good run up and decent beat. Liquid and increasing institutional interest.
Long
Price has broken out of a down channelI see this breaking down slightly back into the channel, forming a right shoulder along the yellow horizontal and then continuing to pursue the reversal above the channelLets see what happens on this Weekly chartBars pattern in green shows my idea
Neutral for nowwaiting for the break out low volume at the moment lets see
11
AUPH: Bulls set to take control
Long
Reversal off supportMarket trading sideways, strong $10 support level. High volume candle with long lower wick rejecting support. RSI at potential double bottom level. Historic support level, showing high potential for reversal to the bull side.
Long
Head and Shoulders projects $9.5-10.50 consolidation zone41% retracement from head to neckline, so 41% from neckline puts it at $10.50. There are multiple horizontal support zones, see chart that also correspond to this zone $9.50 - 10.50. Greenleaf (CEO) is a complete clown. Issuing a statement last week that guidance will likely be aggressive then
Long
Long Auph- Double bottom. ER Monday..Looks like a double bottom to me. risk reward in favor.
Long
$AUPH 200MA broken, Pivot points used to calculate R:R.Noticed Auph broke the 200ma did some quick analysis which means jack all but if we continue on this upward trend were likely to see a breakout soon. TA is based on pivot points with supports. Box means support confirmed over a few candles, ellipses is looking for past supports. This isn't investmen
Long
Keep reading
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Stock brokers
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Interactive Brokers
Featured
4.4Very Good
Learn more
TradeStation
4.4Very Good
Learn more
RoboMarkets
4.0Average
Learn more
Frequently Asked Questions
The current price of
AUPH
is
5.42
USD
— it has decreased by
2.17
% in the past 24 hours. Watch
Aurinia Pharmaceuticals Inc
stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on
NASDAQ
exchange
Aurinia Pharmaceuticals Inc
stocks are traded under the ticker
AUPH
.
AUPH
stock has risen by
1.31
% compared to the previous week, the month change is a
6.55
% fall, over the last year
Aurinia Pharmaceuticals Inc
has showed a
46.07
% decrease.
We've gathered analysts' opinions on
Aurinia Pharmaceuticals Inc
future price: according to them,
AUPH
price has a max estimate of
15.00
USD
and a min estimate of
6.00
USD
. Watch
AUPH chartand read a more detailed
Aurinia Pharmaceuticals Inc stock forecast: see what analysts think of
Aurinia Pharmaceuticals Inc
and suggest that you do with its stocks.
AUPH
reached its all-time high on
Nov 3, 2021
with the price of
33.97
USD
, and its all-time low was
1.00
USD
and was reached on
Sep 10, 2012
. View more price dynamics on
AUPH chart.
See other stocks reaching their highest and lowest prices.
AUPH
stock is
4.07
% volatile and has beta coefficient of
1.92
. Track
Aurinia Pharmaceuticals Inc
stock price on the chart and check out the list of the most volatile stocks — is
Aurinia Pharmaceuticals Inc
there?
Today
Aurinia Pharmaceuticals Inc
has the market capitalization of
775.16 M
, it has increased by
0.94
% over the last week.
Yes, you can track
Aurinia Pharmaceuticals Inc financialsin yearly and quarterly reports right on TradingView.
Aurinia Pharmaceuticals Inc
is going to release the next earnings report on
Aug 1, 2024
. Keep track of upcoming events with our Earnings Calendar.
AUPH
earnings for the last quarter are
−0.07
USD
per share, whereas the estimation was
−0.14
USD
resulting in a
48.78
% surprise. The estimated earnings for the next quarter are
0.01
USD
per share. See more details about
Aurinia Pharmaceuticals Inc earnings.
for the last quarter amounts to
50.30 M
USD
, despite the estimated figure of
47.07 M
USD
. In the next quarter, revenue is expected to reach
54.25 M
USD
.
AUPH
net income for the last quarter is
−10.75 M
USD
, while the quarter before that showed
−26.88 M
USD
of net income which accounts for
60.00
% change. Track more
Aurinia Pharmaceuticals Inc financial statsto get the full picture.
No,
AUPH
doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of
Jun 20, 2024
, the company has
300.00
employees. See our rating of the largest employees — is
Aurinia Pharmaceuticals Inc
on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company.
Aurinia Pharmaceuticals Inc
EBITDA is
−48.74 M
USD
, and current EBITDA margin is
−40.83
%. See more stats in
Aurinia Pharmaceuticals Inc financial statements.
Like other stocks,
AUPH
shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade
Aurinia Pharmaceuticals Inc
stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So
Aurinia Pharmaceuticals Inc
technincal analysis shows the neutral today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating
Aurinia Pharmaceuticals Inc
stock shows the sell signal. See more of
Aurinia Pharmaceuticals Inc technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
